Replies to post #2258 on Ocera Therapeutics fka OCRX

[longx]

I would like to know how Dew knows that. Is there a source?
Let's say it's just 5 percent... that's still 50 million a year in revenue for a company with a market cap currently sitting below 30 million.

Yes, agree 100% on this. Even with only $50M revenue on Rixafimin and a typical Biotech/Drugs company should be valued about 3x revenue; that would translate into $6.52/share (=150/23).

However, it's the huge potential in OCRX (see the slides below) that investors are buying shares at this level.